Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NASD]
Sanofi
Index- P/E33.54 EPS (ttm)1.54 Insider Own16.40% Shs Outstand2.55B Perf Week-0.46%
Market Cap131.62B Forward P/E14.10 EPS next Y3.66 Insider Trans0.00% Shs Float2.23B Perf Month4.11%
Income3.87B PEG4.47 EPS next Q- Inst Own7.60% Short Float0.14% Perf Quarter18.64%
Sales42.89B P/S3.07 EPS this Y-32.80% Inst Trans4.44% Short Ratio1.60 Perf Half Y1.85%
Book/sh26.25 P/B1.97 EPS next Y7.81% ROA- Target Price56.63 Perf Year17.32%
Cash/sh- P/C- EPS next 5Y7.50% ROE- 52W Range37.62 - 52.94 Perf YTD2.83%
Dividend1.70 P/FCF- EPS past 5Y-6.40% ROI3.50% 52W High-2.49% Beta0.60
Dividend %3.29% Quick Ratio- Sales past 5Y3.30% Gross Margin68.00% 52W Low37.21% ATR0.96
Employees100409 Current Ratio- Sales Q/Q6.90% Oper. Margin16.20% RSI (14)55.70 Volatility1.48% 1.72%
OptionableYes Debt/Eq- EPS Q/Q47.40% Profit Margin13.60% Rel Volume0.37 Prev Close51.27
ShortableYes LT Debt/Eq- EarningsApr 24 BMO Payout0.00% Avg Volume1.94M Price51.62
Recom1.40 SMA200.94% SMA504.32% SMA2008.26% Volume720,193 Change0.68%
Mar-17-20Upgrade Barclays Underweight → Equal Weight
Mar-11-20Upgrade Goldman Neutral → Buy
Feb-11-20Initiated SVB Leerink Mkt Perform
Jan-06-20Upgrade JP Morgan Neutral → Overweight
Sep-23-19Upgrade Guggenheim Neutral → Buy
Sep-20-19Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19Initiated Bernstein Outperform
Aug-14-19Upgrade UBS Neutral → Buy
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Jul-03-20 09:54PM  
08:22AM  
08:19AM  
Jul-02-20 10:15PM  
04:59PM  
04:44PM  
Jul-01-20 09:46AM  
07:00AM  
Jun-30-20 09:31AM  
Jun-29-20 05:50PM  
02:06PM  
Jun-26-20 09:13AM  
05:55AM  
05:52AM  
Jun-25-20 03:26PM  
10:23AM  
07:00AM  
Jun-24-20 11:45AM  
09:33AM  
Jun-23-20 04:05PM  
03:28PM  
02:38PM  
01:42PM  
12:23PM  
11:40AM  
10:38AM  
10:28AM  
08:37AM  
07:57AM  
07:10AM  
06:21AM  
06:01AM  
03:57AM  
01:48AM  
01:21AM  
01:17AM  
01:13AM  
01:00AM  
Jun-20-20 12:11PM  
Jun-19-20 05:11PM  
01:51PM  
07:40AM  
07:25AM  
Jun-18-20 12:07PM  
Jun-17-20 10:10AM  
07:48AM  
Jun-16-20 05:21PM  
11:48AM  
11:19AM  
08:13AM  
07:46AM  
06:03AM  
Jun-15-20 05:50PM  
05:00PM  
03:18PM  
12:18PM  
11:37AM  
09:36AM  
07:36AM  
07:00AM  
05:32AM  
Jun-14-20 11:16AM  
10:55AM  
10:20AM  
Jun-13-20 08:21AM  
Jun-12-20 05:01PM  
09:21AM  
08:30AM  
04:37AM  
Jun-11-20 01:12AM  
Jun-10-20 02:03PM  
05:22AM  
Jun-09-20 05:45PM  
04:28PM  
10:31AM  
07:46AM  
Jun-08-20 11:45AM  
10:28AM  
Jun-05-20 06:10PM  
02:00PM  
12:48PM  
11:03AM  
Jun-04-20 11:31AM  
Jun-03-20 01:13PM  
01:03PM  
05:56AM  
Jun-02-20 04:51PM  
07:45AM  
03:07AM  
Jun-01-20 09:57AM  
07:57AM  
07:50AM  
06:07AM  
May-31-20 05:32PM  
May-29-20 11:00PM  
08:59PM  
05:25PM  
03:36PM  
12:22PM  
09:37AM  
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; and GlaxoSmithKline Plc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 09Sale597.48120,23471,837,410279,766Jun 11 06:45 PM
Sanofi10% OwnerMay 29Sale509.852,399,5521,223,411,587400,000May 29 04:16 PM
Sanofi10% OwnerMay 29Sale509.8520,421,89910,412,105,2050May 29 04:16 PM
Sanofi10% OwnerMar 09Sale489.65128,91463,123,15320,421,899Mar 11 05:00 PM
Sanofi10% OwnerSep 10Sale281.15172,90448,611,80420,550,813Sep 12 05:00 PM
Sanofi10% OwnerJul 22Buy16.0093,7501,500,000558,035Jul 23 11:39 AM